Q-omics provides the consensus-scored MIR517B profile across patient tissues and cancer cell-line models. MIR517B expression is associated with patient survival in 4 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, MIR517B is differentially expressed in 1, with the highest sampling consensus in KIRP. Additionally, MIR517B RNA expression shows 6,169 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight TGCT, KIRP, and STAD as cancer lineages where MIR517B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR517B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR517B survival associations across molecular data types. MIR517B RNA expression shows survival associations in the most cancer types (4), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR517B RNA expression–survival associations across cancer types. High MIR517B expression shows unfavorable associations in TGCT and LGG, but favorable associations in STAD and ESCA. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .017). Together, the overview and detailed table identify TGCT as the clearest survival context for MIR517B RNA expression.
This table summarizes MIR517B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for MIR517B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR517B shows higher tumor expression in KIRP. The KIRP box plot shows higher MIR517B RNA expression in tumor versus normal tissue (log2 FC = +0.087, t-test p = .041).
This table shows molecular features associated with MIR517B in patient tissues and cancer cell lines. In patient samples, MIR517B shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
